v3.26.1
SEGMENT INFORMATION (Details) - USD ($)
3 Months Ended 6 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Apr. 30, 2026
Apr. 30, 2025
Accounting Policies [Abstract]        
Revenue $ 2,581,000 $ 1,149,000 $ 4,027,000 $ 2,239,000
Cost of goods sold (526,000) (256,000) (807,000) (447,000)
Salaries & consulting fees (839,000) (716,000) (1,562,000) (1,425,000)
Professional fees (295,000) (137,000) (455,000) (283,000)
Commissions (279,000) (91,000) (465,000) (178,000)
Marketing (238,000) (73,000) (342,000) (114,000)
Stock based compensation (590,000) (1,096,000) (1,182,000) (2,187,000)
Lab expenses (204,000) (39,000) (373,000) (41,000)
Research & development (31,000) (42,000) (50,000) (48,000)
Insurance (47,000) (80,000) (109,000) (106,000)
Office expenses & other (45,000) (13,000) (72,000) (57,000)
Other income (expenses), net (22,000) 3,000 3,000 13,000
Gain on sale of Exotropin interests 390,000 390,000
Net loss $ (145,000) $ (1,391,000) $ (997,000) $ (2,634,000)